Table 1.
Phase 2 and 3 trials comparing 2-year OS with the BED10 across different fractionation schedules.
| Trial | Phase | RT schedule Gy/fr |
Fraction per day |
BED10 (Gy) |
2-year OS (%) |
|---|---|---|---|---|---|
| AT Turrisi (Intergroup 0096) 1999 (11) |
3 | 45/25 45/30 |
1 2 |
39,49 43,91 |
41 47 |
| C Faivre-Finn (Convert) 2017 (12) |
3 | 45/30 66/33 |
2 1 |
43,91 60,64 |
56 51 |
| J Bogart (CALGB 30610(Alliance)/RTOG 0538) 2023 (13) | 3 | 45/30 70/35 |
2 1 |
43,91 64,61 |
58 56 |
| BH Grønberg 2016 (14) |
2 | 45/30 42/15 |
2 1 |
43,91 45,92 |
53 42 |
| B Qiu 2021 (10) |
2 | 45/30 65/26 |
2 1 |
43,91 66,40 |
70 74 |
| BH Grønberg 2021 (15) |
2 | 45/30 60/40 |
2 2 |
43,91 58,28 |
48 74 |
| J Yu 2024 (16) |
3 | 45/30 54/30 |
2 2 |
43,91 55,88 |
54 76 |
RT, radiotherapy; BED, Biologically Effective Dose; OS, Overall Survival.